The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
GV20 received an upfront payment and is eligible for additional milestone payments
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
The company showcased three core programs developed through this platform
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Subscribe To Our Newsletter & Stay Updated
